Powering Drug Discovery with Genomics and Analytics at Biogen

Biogen is interested in addressing neurological conditions of high unmet need including neurodegenerative diseases, pain and neuropsychiatric disorders. Traditional drug discovery and translational model systems have fared poorly for tackling diseases in neurology.  Biogen is building capability and efforts in leveraging both data and methods from cutting edge human biology and genomics to advance novel therapeutic programs.  Of interest are Mendelian randomization methods that speak to causal endophenotypes and pathway relevant biomarkers, quantitative measures of cognition and decline, polygenic risk scores that stratify patients in clinical intervention studies, and genetics of disease progression.